Mathematical Models of Tuberculosis Reactivation and Relapse (Q38848891)

7 September 2017

Mathematical Models of Tuberculosis Reactivation and Relapse (English)

1 reference

7 September 2017

1 reference

1 reference

Robert S Wallis

1

1 reference

7 September 2017

17 May 2016

1 reference

Frontiers in Microbiology

7 September 2017

1 reference

7 September 2017

7

1 reference

7 September 2017

669

1 reference

Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update

7 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Molecular epidemiology of Mycobacterium tuberculosis among South African gold miners

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

A trial of mass isoniazid preventive therapy for tuberculosis control

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Application of a stochastic modeling to assess the evolution of tuberculous and non-tuberculous mycobacterial infection in patients treated with tumor necrosis factor inhibitors

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Validation of analytic methods for biomarkers used in drug development

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Nontuberculous mycobacteria in the environment

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Estimation of the annual risk of tuberculosis infection for white men in the United States

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

A four-month gatifloxacin-containing regimen for treating tuberculosis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Prevalence of latent tuberculosis infection among gold miners in South Africa

22 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Non-linear curve fitting using Microsoft Excel solver.

22 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

22 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.

22 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

22 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Markov models in medical decision making: a practical guide.

22 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4869524

Granulomatous infections due to tumor necrosis factor blockade: correction

22 August 2018

1 reference

12 December 2020

Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes

1 reference

12 December 2020

Antirheumatic drugs and the risk of tuberculosis

1 reference

12 December 2020

Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis

1 reference

12 December 2020

Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity

1 reference

12 December 2020

Identifiers

DOI

10.3389/FMICB.2016.00669

1 reference

7 September 2017

1 reference

7 September 2017

1 reference

PMCID

4869524